Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Prof Nicolas Girard - Institut Curie, Paris, France
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )
7 Apr 2025

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands
Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )
7 Apr 2025

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Subcutaneous pembrolizumab is a viable treatment option for mNSCLC ( Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
7 Apr 2025

Urine test could reduce post-op scans for kidney cancer by half

Dr Saeed Dabestani - Lund university, Lund, Sweden
Urine test could reduce post-op scans for kidney cancer by half ( Dr Saeed Dabestani - Lund university, Lund, Sweden )
27 Mar 2025

Micro-ultrasound is as effective as MRI in detecting prostate cancer

Dr Laurence Klotz - Sunnybrook Health Sciences Centre, Toronto, Canada
Micro-ultrasound is as effective as MRI in detecting prostate cancer ( Dr Laurence Klotz - Sunnybrook Health Sciences Centre, Toronto, Canada )
27 Mar 2025

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada
Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )
27 Mar 2025

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada
Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )
27 Mar 2025

Adjuvant docetaxel shows no significant advantage compared to surveillance in high-risk prostate cancer after 10 years

Dr Pirkko-Liisa Kellokumpu-Lehtinen - Tampere University Hospital, Tampere, Finland
Adjuvant docetaxel shows no significant advantage compared to surveillance in high-risk prostate cancer after 10 years ( Dr Pirkko-Liisa Kellokumpu-Lehtinen - Tampere University Hospital, Tampere, Finland )
26 Mar 2025

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy

Dr Sarah Psutka - University of Washington, Seattle, USA
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )
26 Mar 2025

EAU 2025: Updates in NMIBC

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone
EAU 2025: Updates in NMIBC ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone )
25 Mar 2025

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer

Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA
Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer ( Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA )
17 Mar 2025

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )
11 Mar 2025